Skip to main content
Equibles
NRIX logo

NRIX · Nurix Therapeutics, Inc. · Metrics

Track NRIX — free

Use NRIX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NRIX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$25.34 -0.17 (-0.67%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$2.77B
Shares
109.25M
Volume · Oct 23 1.91M Avg daily vol (3M) 1.62M

NRIX metrics

74 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$25.34
Market cap
$2.77B

Price action

20 metrics
Price change (1W)
+3.8%
Price change (30D)
+10.1%
Price change (3M)
+8.4%
Price change (6M)
+51.9%
Price change (YTD)
+33.6%
Price change (1Y)
+143.7%
Trailing year
Price change (5Y)
-9.7%
52-week high
$27.79
52-week low
$10.40
Change from 52-week high
-8.8%
Change from 52-week low
+143.7%
Annualized volatility
56.0%
Annualized volatility (3M)
37.0%
Beta
1.3
RSI (14D)
57.7
Price vs SMA 50
+1.2%
Price vs SMA 200
+26.8%
Avg volume (3M)
1.62M
Relative volume
1.2
Average dollar volume
$40.08M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
109.25M

Valuation

12 metrics
P / E (TTM)
11.0
Trailing earnings · reciprocal yield 9.1%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.9×
reciprocal yield 25.4%
P / book
2.9
reciprocal yield 35.0%
FCF yield
13.4%
TTM · current market cap
Buyback yield
—
P / FCF
7.5
reciprocal yield 13.4%
P / operating cash flow
7.3
reciprocal yield 13.7%
Earnings yield
10.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-08

Profitability

9 metrics
Gross margin
—
Operating margin
41.3%
Trailing 12 months
Net margin
42.0%
Gross profit (TTM)
—
Operating profit (TTM)
$289.66M
Net income (TTM)
$294.88M
Trailing 12 months
Diluted EPS (TTM)
$2.30
FCF margin
52.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.29

Growth

11 metrics
Revenue growth YoY
+8,426.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$701.94M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+38.0%
Year over year · more shares
Revenue CAGR (3Y)
+29.5%
Revenue CAGR (5Y)
+36.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
30.5%
Return on assets
24.7%
Debt / equity
—
Current ratio
8.4
EBITDA (TTM)
$298.37M
Free cash flow (TTM)
$369.81M
Quick ratio
8.4
Interest coverage
—
Net debt / EBITDA
-2.4
Return on invested capital
—
Trailing 12 months
Net cash
$720.24M
Latest balance sheet
Cash & equivalents
$720.24M
Total assets
$1.20B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$379.31M
Capital expenditures (TTM)
$9.50M
R&D (TTM)
$334.07M
SG&A (TTM)
—
Stock compensation (TTM)
$40.66M
R&D / revenue
47.6%
Stock compensation / revenue
5.8%

Ownership (13F)

9 metrics
13F filers
213
13F filer change QoQ
+16
Institutional ownership
107.6%
Conviction holders (share of 13F filers)
2.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+2.0%
Holder tenure
13.1
Price vs estimated holder cost
+47.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.8%

Short interest

3 metrics
Short interest
16.2%
Latest settlement · 9.9 days to cover
Days to cover
9.9d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.80M
Insider-sentiment score
24 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1549595 CUSIP 67080M103 13F (30d) 18 filings 18 filers Visit website Investor relations